Study of Desmoteplase (International Nonproprietary Name [INN]) in Acute Ischemic Stroke (DIAS-2)

Inclusion Criteria: * Eligible for study treatment within 3-9 hours after onset of stroke symptoms. * Score of 4-24 on the NIHSS with clinical signs of hemispheric infarction (i.e. hemiparesis) suggestive of ischemic stroke. Inclusion Criteria from diagnostic imaging screening: * Distinct penumbra (at least 20%), measured by MRI (PWI/DWI) or perfusion CT, related to middle cerebral artery (MCA), anterior cerebral artery (ACA), or posterior cerebral artery (PCA) territory in a hemispheric distribution. Exclusion Criteria: * History or clinical presentation of intracranial hemorrhage (ICH), subarachnoid hemorrhage, arteriovenous malformation, aneurysm, or cerebral neoplasm. * Rapidly improving neurological symptoms. * Pre-stroke MRS score of \> 1 (including previous disability). * Suspected acute vertebral or basilar artery occlusion. * Current use of anticoagulants and a prolonged prothrombin time. * Uncontrolled hypertension. * Baseline hematocrit of \< 0.25. * Baseline platelet count \< 100,000/mm3.